Objective:

To synthesize evidence supporting GLP-1 and GLP-2 as therapeutic agents for intestinal repair in inflammatory bowel disease (IBD), emphasizing their significance in the evolving treatment landscape.

Key Findings:

• IBD is characterized by chronic inflammation and a loss of gut epithelial barrier integrity, with specific examples of how this manifests in patients.
• Current therapies have shifted focus from symptom control to achieving intestinal reparative therapy with objective endpoints, such as endoscopic healing.
• GLP-1 and GLP-2 play significant roles in promoting mucosal healing and modulating inflammation, with evidence supporting their efficacy.

Interpretation:

GLP-1 and GLP-2 represent promising therapeutic agents for enhancing intestinal repair in IBD, potentially improving long-term patient outcomes through specific mechanisms.

Limitations:

• The review primarily synthesizes existing data without presenting new experimental findings, which may limit the depth of analysis.
• Further clinical trials are necessary to establish the efficacy and safety of GLP-1 and GLP-2 in IBD treatment, considering potential biases in observational studies.

Conclusion:

Targeting GLP-1 and GLP-2 pathways may offer novel strategies for managing IBD, emphasizing the urgent need for further research to validate these approaches.